Search 

ABIGO Medical AB is a Swedish pharmaceutical company which owns, develops, produces and markets pharmaceuticals and medical device products. The prime area for the medical device products are advanced wound care and ENT.

For the international markets ABIGO Medical focus on unique solutions in advanced wound care and ear, nose and throat (ENT).

Alzinova AB is a privately held Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. A platform technology based on the AβCC™ peptides provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.

Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy in a Eurostars-funded project. Non-toxic mimetic amyloid-β are investigated as replacement therapy. The unique properties of the AβCC™ peptide platform technology has also enabled the development of a monoclonal antibody with 100% specificity for the disease-driving oligomers.

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The Company's pipeline currently includes three product candidates for the treatment of cancer.

Our mission is to generate value for shareholders by building a sustainable portfolio of clinical development projects and, over time, successfully launching several innovative drugs.

In order to maximise the value of the Company we plan to:

• Commercialise product candidates in co-operation with partners.
• Retain rights to individual geographic markets for particular products where we consider that it would be feasible to establish a competitive sales and marketing force.
• Broaden and expand our product portfolio to create more opportunities for generating successful products and increasing the likelihood of commercial success for the Company as a whole.
• Gain access to innovative target proteins and/or projects from external research groups and use these as a basis for generating novel therapeutics using our proprietary technology platform.

Our revenues include licence fees, milestone payments, compensation of manufacturing and royalties on sales derived from our co-operation agreements around our product candidates. We also generate income by providing discovery development to our customers.

We expect to achieve sustainable profitability as soon as one of our products reaches the market. However, profits may be reported in certain years before this as projects reach key milestones that trigger payments from partners.

• controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
• ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
• effective industrial rollout of their technologies;
• alongside leading partners, involvement in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs.

• To industrialize pluripotent stem cells;
• To develop industrial in vitro tools predictive of human physiology and genetic diversity, such as tools for the drug and cosmetic industries, as well as for research, and that can be immediately used in industrial molecular screening and selection processes;
• To develop major partnerships, particularly in the field of regenerative medicine;
• To take a strategic industrial role in order to set standards in an emerging market, forge a strong pioneering position in the areas of focus, and build a genuine industrial sector based around stem cells and a competitive industrial cluster.

• Dan Peters has >20 years of experience in pharmaceutical discovery and
  development as a key scientific and management leader at NeuroSearch A/S
• PET is a nuclear medicine technique for non-invasive, real-time 3D-imaging
  of physiological processes in the brain and other organs
• Development of best-in-class nicotinic alpha-7 PET ligands (11C-NS14492 and 18F-NS10743)
• 11C-NS14492 and 18F-NS10743 have potential for guiding diagnosis and treatment of Alzheimer’s Disease (Psychopharmacology (2006), 188(4), 509-520)
• High quality NET-PET ligands (11C-NS8880 and 18F-NS12137)
• SERT–PET ligands (11C-NS6417, 11C-NS9531 and 11C-NS9762)
• Broad IP portfolio within several classes with major focus on the EU and US-market
• DanPET owns IP-rights for the ligands mentioned above

iliod is a pharmaceutical development company aiming at developing a novel infective agent until phase II clinical trials. iliod is founded on the core assets of three patent applications, know-how and experience of the active protein, a network both within academia and industry and a dedicated team with a drive to make a difference for the future of healthcare.

Immunicum AB (publ) develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX®, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be mass-produced.

The therapeutic cancer vaccine INTUVAX® is injected intratumorally and is currently being evaluated in a clinical Phase I/II-study in metastatic renal cell carcinoma. It utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely personalized therapeutic cancer vaccine that is still able to mass-produce and store in frozen condition for long periods of time.

Lavivo helps you to a sound and healthy life, with the help of products that prevent bacterial infections and that create an ecological bacterial balance.

Lavivo was incorporated with the vision to offer products that help you achieve a balanced gastrointenstinal tract and avoid bacterial infections.

Lavivo has choosen to initially focus on synbiotic products, including beneficial bacteria (probiotics) and metabolic fibres (prebiotics), with smart delivery for optimal efficacy.

Through close cooperation with scientists and experts within the focused technologies Lavivo can offer products based on the latest developments in research.

Lavivo manufactures and markets the AptiCare® products.

Lavivo is situated in Göteborg, at the west coast of Sweden.